𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation

✍ Scribed by Wolfgang Hagmann; Ralf Jesnowski; Johannes Matthias Löhr

Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
101 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

With great interest, we read the recent publication ''CD44positive cells are responsible for gemcitabine resistance in pancreatic cancer cells'' by Hong et al. 1 In this study, the authors established gemcitabine-resistant pancreatic cancer cells in vitro and characterized them in various ways, in vitro and in vivo. The authors describe these gemcitabineresistant cells as being more tumorigenic in vitro and in vivo as judged from colony formation assays and tumor

📜 SIMILAR VOLUMES

CD44-positive cells are responsible for
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
✍ Sung Pil Hong; Jing Wen; Seungmin Bang; Seungwoo Park; Si Young Song 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 318 KB

## Abstract Accumulating evidence suggests that tumors are composed of a heterogeneous cell population with a small subset of cancer stem cells (CSCs) that sustain tumor formation and growth. Recently, there have been efforts to explain drug resistance of cancer cells based on the concept of CSCs h

Selenoprotein P, as a predictor for eval
Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells
✍ Shin-ichiro Maehara; Shinji Tanaka; Mitsuo Shimada; Ken Shirabe; Yoshiro Saito; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 252 KB

## Abstract Gemcitabine is a new standard chemotherapeutic agent used in the treatment of pancreatic cancer, but the mechanisms of gemcitabine sensitivity are still controversial. In our study to determine a mechanism that regulates gemcitabine sensitivity, we carried out molecular analysis on the